CELH
$23.77 at the check
SHORT

Kairon's answer on CELH: not yet.

Leaning down, but not enough conviction for a trade.

Checked Aug 7, 2026 at $23.77, time frame Not applicable – not a swing trade. Tactical 1-2 week window only., confidence high
Why? For, against, what would change it
  • ForDespite trailing PE signaling historic overvaluation, forward PE and PEG reflect materially discounted valuation relative to expected earnings growth.
  • AgainstGrowth is sharply decelerating after hyper-growth phase.
Result after 20 trading days: wrong (+9.6 % vs. SPY, stock +8.6 %, graded Sep 8, 2026).

The 10-second check

Loading filings…

Both sides

More for

Management has repeatedly outperformed consensus estimates, with four consecutive quarters of >+37% EPS beats.

CELH maintains a healthy balance sheet—low leverage, robust liquidity, and positive free cash flow.

More against

Historic dilution eroded returns for long-term holders and continues to weigh on per-share growth.

Subpar profitability means CELH may be structurally handicapped vs entrenched “moat” peers.

Read the full debate between the bull and the bear analyst

Bull Analyst: BULL CASE ARGUMENTS

---

Argument 1 – Valuation vs Growth (Conviction: HIGH)
Evidence: PEG ratio 0.3; Forward PE 12.29; Forward EPS forecast $1.93 (vs TTM $0.35, +452%); Fundamental Score 4.5/10
Thesis: Despite trailing PE (67.91) signaling historic overvaluation, forward PE (12.29) and PEG (0.3) reflect materially discounted valuation relative to expected earnings growth. If forward consensus is met, shares are fundamentally cheap versus prior hyper-growth peers, presenting an asymmetric risk/reward profile. The risk is strictly tied to delivering growth, not multiple contraction.

---

Argument 2 – Earnings Surprise + Operational Leverage (Conviction: MEDIUM)
Evidence: Last 4 quarters EPS beats: +93%, +52%, +37%, +40%; 1y EPS growth +38.1%; 1y sales growth +34.6%.
Thesis: Management has repeatedly outperformed consensus estimates, with four consecutive quarters of >+37% EPS beats. This suggests analyst forecasts may be too conservative given demonstrated operational leverage and execution. The firm’s ability to deliver surprise growth supports the case for mean-reversion in sentiment and technicals once short-term slowdown fears abate.

---

Argument 3 – Balance Sheet and Free Cash Flow (Conviction: HIGH)
Evidence: Current ratio 1.77; Net debt/equity 22.45%; FCF (TTM) $177.8m; Positive cash from operations; no ongoing losses flagged.
Thesis: CELH maintains a healthy balance sheet—low leverage, robust liquidity, and positive free cash flow. The company is not dependent on dilutive capital raises or speculative turnarounds. This financial stability supports long-term growth investments and reduces existential risk even amidst share price volatility.

---

Argument 4 – Insider Ownership Alignment (Conviction: MEDIUM)
Evidence: Insider ownership 28.6%.
Thesis: High insider ownership signals management is financially aligned with shareholders. This reduces agency risk and supports continuity of growth plan execution, particularly in consumer-branded businesses where founder alignment often correlates with successful scale-ups.

---

Argument 5 – Tactical Mean-Reversion Opportunity (Conviction: MEDIUM)
Evidence: RSI 20.9 (deeply oversold); ATR 3.01 (7% of price); quant mean-reversion signals +100; Quant Monte Carlo forward return +2.3% (+0.59% median), P(up) 51.4%; Key support $39.00, upside base target $45.08 (VWMA) = 3:1 R/R.
Thesis: From a market-tactical angle, CELH is deeply oversold. Multiple quant and technical indicators (RSI, mean-reversion) predict increased likelihood of at least a short-term bounce toward VWMA ($45.08), offering a favorable risk/reward for disciplined traders. Macro (SPY in Bull regime) aligns with a tactical long thesis, though conviction is strictly short-term.

---

BEAR COUNTER-ARGUMENTS

---

Bear said: "+232% share dilution in 3y—extremely negative for holders."
Counter: Despite dilution, company achieved 1y EPS growth of +38.1%, TTM sales +34.6%, and positive FCF ($177.8m). This implies new shares drove real growth, not just financial engineering. As shares outstanding stabilize (no recent ongoing dilution flagged), operating growth now outpaces dilution.

---

Bear said: "Estimate revisions sharply negative: e.g., Q0 EPS from 0.462 to 0.418 (-9.5%) over 90d."
Counter: Even after downward revisions, forward EPS consensus is $1.93, a +452% increase over trailing EPS ($0.35). Historical beat streak (+93% to +40% surprises) suggests analysts underestimate execution, so consensus may be overly pessimistic.

---

Bear said: "PE (TTM) 67.91 is nosebleed level."
Counter: Forward PE is 12.29—over five times lower. PEG at 0.3 is historically cheap for growth stocks, provided current growth is sustained. The trailing PE reflects past hyper-growth and expansion; forward multiples contextualize present opportunity.

---

Bear said: "Profit margin (5.85%), ROE (8.1%), and high analyst target dispersion are weak."
Counter: Operating margin is 19.8% (solid for beverage sector) and profit margin up markedly YoY. High analyst dispersion is typical in transition periods (growth slowdown) but also often precedes mean-reversion if fundamentals outpace consensus caution. Ongoing positive FCF and low leverage bolster quality, even if headline margins lag peer leaders.

---

Bear said: "Short interest dangerously high (15.9%), risk of squeeze-out or further selling."
Counter: High short interest can act as fuel for a tactical mean-reversion rally if technicals stabilize. Quant mean-reversion scores (+100) and RSI (20.9) indicate extreme oversold. Previous large earnings beats show high risk for shorts during such periods.

---

BULL THESIS INVALIDATION LEVEL

The bull thesis breaks if:
- Price closes below $38.80 (recent low/stop-loss), confirming failed mean-reversion setup and breakdown of technical support.
- Next earnings show revenue growth <10% YoY _and_ miss consensus forward EPS ($1.93), invalidating the fundamental growth thesis supporting PEG/forward PE.

---

OVERALL BULL CONVICTION: MEDIUM (5-7 out of 10)

Justification:
- Two high conviction arguments: valuation vs growth (PEG 0.3, fwd PE 12.3) and balance sheet/FCF support.
- Three medium conviction arguments: earnings beat streak (but growth slowing), insider alignment, tactical mean-reversion (very short-term, volatile).
- Majority of evidence is backward-looking and forward signals (technical/quant) are weak for longer horizon.
- Macro regime is positive (SPY bull), but CELH is decoupled. Quant conflicts (mean reversion bullish, trend/momentum bearish) necessitate caution.
- Suitable as a disciplined tactical trade or watchlist candidate, not a high-conviction long-term fundamental allocation until growth re-accelerates and technicals stabilize.
Bear Analyst: BEAR CASE RISKS

---

Risk 1 – Fundamental Growth Slowdown & Estimate Revisions [HIGH conviction]
Evidence: 1Y Sales Growth: +34.6% and 1Y EPS Growth: +38.1%, but next year consensus: revenue growth +6.6%, EPS growth +6.6%. Short-term EPS estimate cut from 0.462 (90d ago) to 0.418 (now, -9.5%); +1q cut from 0.481 to 0.423 (-12.1%); full-year 2026 revised downward.
Risk: Growth is sharply decelerating after hyper-growth phase. This “slowing from high” is exactly when multiples compress and sentiment flips. If CELH grows only 6.6% instead of 34.6%, the forward PE (currently 12.3) could re-rate back toward sector median, especially if further estimate cuts continue.
Quantified downside: If PE compresses from 12.3x (current fwd) to a more typical 9x for slowing growth, and EPS misses consensus (drops to $1.60 instead of $1.93), price = 9 × 1.60 = $14.40 (vs $40.38 now) — a 64% downside scenario.

---

Risk 2 – Massive Share Dilution Hangover [HIGH conviction]
Evidence: Share count up +232% in 3y (from ~77m to 255.6m shares out); enormous compared to any non-distressed peer.
Risk: Historic dilution eroded returns for long-term holders and continues to weigh on per-share growth. Even if growth now stabilizes, prior value destruction is evidenced in poor 3y returns. If organic growth slows further or additional shares are issued, the equity will structurally underperform.
Quantified downside: Average high-growth consumer names with 200%+ dilution and slowing growth see 30–50% further underperformance vs index over subsequent 2–3 years (based on comps: BYND, NKLA post-dilution busts).

---

Risk 3 – Weak Profitability & Quality Metrics [MEDIUM conviction]
Evidence: Profit margin 5.8% (low for sector); ROE 8.1% (vs consumer staples median: 18%+); Analyst target dispersion is 105% of mean (low analyst conviction). Operating margin 19.8% but markedly below leaders.
Risk: Subpar profitability means CELH may be structurally handicapped vs entrenched “moat” peers (KO, PEP). Earnings quality is questionable given historic dilution and modest margins. Wide analyst target spread signals risk of further downgrades/volatility.
Quantified downside: If margin stays sub-scale and/or compresses (profit margin <5%), CELH could be re-rated to book value proxies (P/B 4.88 drops to sector 2.5x: price falls to $20, a 50% downside from here).

---

Risk 4 – Severe Downtrend & Technical Breakdown [MEDIUM conviction]
Evidence: Price is -37% below 200MA ($40.38 vs $64.49); RSI 20.9 (deeply oversold but no reversal); 50MA sloping sharply lower; technical score 2.1/10. Quant ‘momentum’ and ‘trend’ signals at -97 to -100.
Risk: Historically, stocks with this magnitude of technical breakdown and high volatility (daily VaR 6.19%, max drawdown 63%) do not “V-shape” recover unless there is a major catalyst. Sustained technical weakness can trigger further stop-outs, force-selling, and loss of institutional support.
Quantified downside: If momentum/trend persists, expect retest of support ($39.00) and possible drop toward post-pandemic base levels at $24–$30 (another 25–40% down), especially if the broader market sours.

---

Risk 5 – High Short Interest, “Broken Story” Signal [LOW conviction—for bear squeeze only]
Evidence: Short interest 15.9% of float (39.94m shares); among highest in consumer sector.
Risk: While bulls view this as “squeeze fuel,” high short interest typically signals fundamental skepticism and often foreshadows new institutional shorts or post-earnings gaps down in failed growth stories. If shorts are right, further downside can be swift and severe.
Quantified downside: If short thesis is validated (missed growth, poor guide), quick re-rating towards support can deliver 20–30% additional downside in under a quarter.
*(If squeeze, short-term countertrend bounces are limited; see quant output for low conviction on sustained rally.)*

---

BULL COUNTER-ARGUMENTS

---

- Bull said: “PEG 0.3, Fwd PE 12.29, Fwd EPS $1.93 (+452% YoY): stock is cheap on growth-adjusted metrics if consensus is met.”
Counter: Consensus is rapidly falling: 1Y forward EPS forecast cut -9.5% (to 0.418 this qtr), and -12.1% next qtr, over just 90 days. If forward growth is not delivered, PEG/PE arguments vanish: a PEG of 0.3 is only valid if growth re-accelerates, which ALL available evidence (revisions, technicals) contradicts.

- Bull said: “Management beat 4 quarters in a row (+93% to +40% EPS surprises); consensus may be too low.”
Counter: No forward “beat” can be assumed: quant momentum/trend signals (-97/–99) and 1Y sales/EPS growth are already dropping to +6.6% consensus in 2025, not the hyper-growth regime that fueled past beats. Estimate cuts outnumber raises 9-to-1 in the latest 30d — analysts are getting LESS confident, not more. Statistically, prior beat streaks often end here when growth decelerates.

- Bull said: “Balance sheet sound—current ratio 1.77, net debt/equity 22.5%, FCF positive $177.8m.”
Counter: While liquidity/solvency is not at issue, balance sheet alone cannot protect equity holders from profit margin drop (from 5.8% to sector median ~10%) and impending EPS disappointments. The prior dilutive playbook (232% increase in shares) is an existential red flag in shareholder trust.

- Bull said: “Insider ownership 28.6%, alignment high.”
Counter: High insider stake does NOT guarantee price support. History (e.g., NKLA, BYND, even SNAP post-lockup) is full of heavily insider-owned companies that tanked when growth slowed or dilution shocked. Absent insider buying at current prices (no recent activity flagged), alignment is theoretical, not proven.

- Bull said: “Deeply oversold; quant mean reversion/RSI/short interest setup for rally.”
Counter: Systematic signals show momentum/trend/volatility signals universally negative: trend -97 to -99 (quant), price -37% below 200MA, negative Sharpe (-2.34), max drawdown -63%, DAILY VaR -6.2%. RSI at 20.9 does not guarantee bounce: price can stay “oversold” for months in broken growth names (see TDOC, PTON history). Tactical mean reversion is unreliable in structurally broken trends. Any bounce is for scalps only.

---

RED FLAGS FROM ANALYST REPORTS

- +232% increase in share count (dilution) in past 3 years.
- High short interest: 15.9% (near-maximum for consumer sector).
- Analyst estimate revisions trend: “Falling”—last 3 quarters/years all cut, 9 downgrades to 1 upgrade in the past month.
- Profit margin only 5.8% (sector leaders: typically 10–17%).
- Target price dispersion: 105% of mean—analysts have very low conviction/consensus.
- Deep technical breakdown (price 37% below 200MA; quant technicals <3/10).
- Max drawdown: 63%.

---

BEAR THESIS CONFIRMATION SIGNAL

The bear thesis accelerates if:
- Weekly close below $39.00 (key support and recent low), OR
- Consensus revenue growth for FY2025 revised <5%, or EPS revised below $1.60, OR
- Further 5%+ downward cut to forward estimates/another 15%+ drawdown post-earnings, indicating NO mean reversion even after deep oversold readings.

---

OVERALL BEAR CONVICTION: HIGH (8/10)

Justification:
- Two HIGH conviction risks (decisive growth deceleration + catastrophic dilution).
- Red flags are overwhelming: downward estimate revisions, technical and quant breakdown, sharply negative momentum, and low profitability vs peers.
- Even with “macro regime Bull” (SPY +4.8% above 200MA), CELH is radically underperforming and not participating, indicating story/stock-specific issues.
- Mean-reversion/oversold tactical longs are strictly for *scalpers* — this is NOT a credible high-conviction long until growth/estimates/technicals bottom and reverse (not in evidence).
- Empirically, stocks with these characteristics have below-average recovery odds and often re-rate down another 30–60%.
- Position size for new money: minimal, or avoid.

---

Summary:
CELH faces a *structural growth slowdown, severe dilution overhang, loss of confidence/divergent analyst views, and major technical breakdown.* Bounces are possible, but risk-reward for medium-term longs is NEGATIVE. Allocation: Avoid or underweight.
Only scenario for turn: clear stabilization of estimates and technical structure. Not present.

Want a fresh check?

A new AI check reads today's prices, news and filings. Compact check: one per month free with an account, ready in a few minutes. Full check with every analyst and chart technicals: in a plan or €3.99 once, about 10 minutes.

Start a new AI checkCheck your own entry (free)

Kairon's record on CELH

1 past checks: 1 directional calls (0 right, 1 wrong). Measured by price since each check, no costs. How we measure. Every 'not now' answer.

Aug 7, 2026: Short at $23.77, +19.7 % sincewrong

Insider and Congress filings

Loading…

Official SEC Form 4 and House PTR filings. Returns run from the first close after a filing became public. A filing is a fact, not a recommendation.

Full report (technical terms)

Key levels

Support$39.00
Resistance$45.08
HorizonNot applicable – not a swing trade. Tactical 1-2 week window only.
Quant score-32/100

Executive summary

Despite a setup for a tactical mean-reversion bounce with strong R/R (3–4:1), CELH is overwhelmingly in a structural downtrend, with technical and quant signals deeply negative and conviction far below the threshold required for allocation. Risks of gap-downs, high short float, and negative estimates are substantial. Only ultra-low size, strictly disciplined scalps would be justified, but due to conviction <7/10 per mandated risk controls, NO_TRADE is warranted. Only re-evaluate upon clear improvement in trend, momentum, or technical confirmation above $43.78/$45.08.

Investment thesis

Extreme mean-reversion signals (RSI <21, zscore, volume flush) provide a tactical scalp opportunity, but all trend/momentum and fundamental signals are deeply negative, indicating structural deterioration and incomplete evidence for reliable bounce. High short interest may support both snapback rallies and sharp liquidations. Fundamental lessons and historic backtest results caution explicitly against trading against a persistent downtrend, especially when volatility is elevated (ATR >7% of price, daily VaR -6%) and conviction is insufficient. The quant composite, risk managers, and technical scores unanimously indicate conviction is far below the allocation threshold; thus, trade is filtered out by risk governance.

Valuation assessment

CELH is trading 37% below its 200MA, with an oversold RSI (20.9), extreme momentum breakdown, and negative fundamental trends. Despite a bullish macro regime (SPY +4.8% above 200MA), CELH is radically decoupled and underperforming, with technical and quant scores indicating persistent downtrend and elevated risk.

Scenario analysis

Bull case: Oversold reversal delivers +7–12% pop if volume/trigger confirms; base probability ~35%. Bear case: Trend persists, failed reversal leads to gap-down toward $36.30 (-9.2%), probability 12%. Base bear: Minor flush to $39.00 (-2.5%) likely, quick stop-out routine. Only viable on strict reversal entry. Trade should be re-evaluated if momentum/trend scores improve or price confirms technical stabilization.

Key risks

Conviction is low (max 3/10), with major risks including severe technical breakdown, high volatility (ATR 7.5% of price), high short interest (15.9%) that could trigger an outsized gap-down if support fails, and negative estimate/fundamental trends. Stop-loss is tight, but gap/tail risk is high. No options/relative strength data available, sector confirmation absent.

AI-generated. Created 2026-08-07 06:31 UTC automatically by Kairon AI (Cem Salomon Weidner, Vienna, Austria) at a price of $23.77. Valid for its time frame from that moment; it is not updated afterwards. Facts come from public sources (Yahoo Finance and others, partly delayed); the rating, levels and scenarios are opinions of the AI. General information, not investment advice and not a solicitation to buy or sell. Conflicts of interest, methodology and risks: disclosure. Every past call and its outcome: track record.

Open this analysis in the app

More checks

Learn the method

Kairon AI is an automated research and second-opinion tool, not a licensed financial advisor, broker, or investment manager. All assessments are AI-generated opinions based on public data and are informational only — not personal investment advice. Investing carries risk, including total loss of capital.

Impressum Privacy Terms Disclaimer